263 related articles for article (PubMed ID: 27708722)
1.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
2. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
3. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
4.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
5. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
7. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
Dietrich D; Hasinger O; Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Wernert N; Perner S; Freedland SJ; Corman JM; Ittmann MM; Lark AL; Madden JF; Hartmann A; Schatz P; Kristiansen G
J Mol Diagn; 2013 Mar; 15(2):270-9. PubMed ID: 23266319
[TBL] [Abstract][Full Text] [Related]
8. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
[TBL] [Abstract][Full Text] [Related]
10. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
[TBL] [Abstract][Full Text] [Related]
11. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
12. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
Li X; Zhang W; Song J; Zhang X; Ran L; He Y
Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
[TBL] [Abstract][Full Text] [Related]
13. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
17. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
19. Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.
Semaan A; Uhl B; Branchi V; Lingohr P; Bootz F; Kristiansen G; Kalff JC; Matthaei H; Pantelis D; Dietrich D
Clin Colorectal Cancer; 2018 Jun; 17(2):e385-e393. PubMed ID: 29580650
[TBL] [Abstract][Full Text] [Related]
20. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.
Schatz P; Dietrich D; Koenig T; Burger M; Lukas A; Fuhrmann I; Kristiansen G; Stoehr R; Schuster M; Lesche R; Weiss G; Corman J; Hartmann A
J Mol Diagn; 2010 May; 12(3):345-53. PubMed ID: 20304943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]